New Research: Combination Approach Improves Survival in Advanced Lung Cancer Patients

A clinical trial recently published in the Journal of Clinical Oncology that combined stereotactic body radiation therapy with chemotherapy more than doubled survival rates in stage IV lung cancer patients.

The clinical trial, led by researchers from UT Southwestern Medical Center, involved 24 patients with advanced lung cancer whose cancer had continued to spread during their initial therapy.

The combination of SBRT with erlotinib chemotherapy resulted in median overall survival of 20.4 months compared to six to nine month overall survival in patients treated with chemotherapy alone. The treatment approach also yielded an improvement in progression-free survival of 14.7 months compared to two to four months in similar lung cancer patients.

Results from this trial concluded that this combined treatment approach may yield better cure rates in certain instances, particularly in metastatic cancers.

To read more about results from this clinical trial, click here. If you or a loved one has been diagnosed with metastatic lung cancer, contact our center to learn more about CyberKnife® and whether you may be a candidate for treatment.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.